{"filing":{"accession_number":"0001628280-26-060880","cik":"0001868419","ticker":"CYCUW","company_name":"Cycurion, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-03","primary_document":"cycu-20260903.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1868419/000162828026060880/cycu-20260903.htm"},"events":[{"id":31928,"run_id":29325,"accession_number":"0001628280-26-060880","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cycurion announced approximately $800,000 in annual contract spend across multiple new commercial engagements, including a pharmaceutical AI Center of Excellence engagement and a NACCHO award. This represents execution of the company's stated commercial expansion strategy into healthcare and life sciences. While not a single discrete operational event like a major contract or partnership, the announcement of multiple material commercial wins that advance the company's strategic direction and demonstrate market traction constitutes a material operational disclosure warranting investor attention.","company_name":"Cycurion, Inc.","ticker":"CYCUW","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34967,"accession_number":"0001628280-26-060880","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cycurion announced approximately $800,000 in annual contract spend across multiple new commercial engagements, including a pharmaceutical AI Center of Excellence engagement and a NACCHO award. This represents execution of the company's stated commercial expansion strategy into healthcare and life sciences. While not a single discrete operational event like a major contract or partnership, the announcement of multiple material commercial wins that advance the company's strategic direction and demonstrate market traction constitutes a material operational disclosure warranting investor attention.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T19:17:05.286448+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34967,"accession_number":"0001628280-26-060880","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cycurion announced approximately $800,000 in annual contract spend across multiple new commercial engagements, including a pharmaceutical AI Center of Excellence engagement and a NACCHO award. This represents execution of the company's stated commercial expansion strategy into healthcare and life sciences. While not a single discrete operational event like a major contract or partnership, the announcement of multiple material commercial wins that advance the company's strategic direction and demonstrate market traction constitutes a material operational disclosure warranting investor attention.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T19:17:05.286448+00:00","company_name":"Cycurion, Inc.","ticker":"CYCUW","filing_date":"2026-09-08"}]}